A groundbreaking medical advancement in Israel promises to restore mobility to paralyzed individuals by using their own cells for spinal cord implants.
Story Highlights
- Israel prepares for the first human spinal cord implant using patient-derived cells.
- Success in animal trials with over 80% regaining full mobility.
- Compassionate-use trials approved for eight patients.
- Potential to transform spinal cord injury management worldwide.
World’s First Personalized Spinal Cord Implant in Israel
In a significant leap for regenerative medicine, Tel Aviv University’s Sagol Center for Regenerative Biotechnology is spearheading the world’s first human spinal cord implant using tissue engineered from the patient’s own cells. This pioneering approach, led by Professor Tal Dvir, aims to restore walking ability to paralyzed patients. The technology has shown unprecedented success in animal models, with over 80% regaining full mobility. Human trials are set to begin within the year, marking a potential revolution in spinal cord injury treatment.
Using a patient’s own blood and fat cells, the engineered spinal cord tissue reduces the risk of rejection, a common barrier in transplant medicine. This personalized implant has shown promising results in animal trials, leading to regulatory approval for compassionate-use human trials in Israel. This groundbreaking development is not only a testament to Israel’s leadership in medical innovation but also offers hope to millions living with paralysis.
The Road to Human Trials
The journey to this medical breakthrough began in 2018 when Dvir’s team started applying tissue engineering technology to the spinal cord. By 2022, they successfully engineered human spinal cord tissue in the lab. The subsequent animal trials demonstrated high efficacy in restoring mobility, prompting regulatory interest and approval for human trials. As of August 2025, preparations for the first implant are underway, with patient selection and surgical planning in progress.
Matricelf, an Israeli biotech startup co-founded by Dvir, is commercializing the technology. The company aims to lead the regenerative medicine market, addressing a multi-billion-dollar unmet need. With the Ministry of Health granting trial approval, the first surgery is set to take place in Israel, positioning the country at the forefront of this medical frontier.
Implications and Future Prospects
The potential implications of this breakthrough are vast. If successful, the implant could transform spinal cord injury management, shifting from palliative to restorative care. This approach could be expanded to treat chronic and older injuries, as well as other neurodegenerative conditions. The success of these trials could also accelerate personalized medicine and tissue engineering research, attracting increased investment in biotech startups and translational research.
While the optimism surrounding this development is high, experts caution that human trials may face unforeseen challenges not present in animal models. Long-term safety and efficacy remain key areas for rigorous clinical validation and regulatory oversight. Nonetheless, the personalized nature of the implant, which overcomes immune rejection and achieves functional integration, has the potential to redefine standards of care globally.
